Artificial transcription factors comprising a sliding domain and uses thereof

Patent metadata

Field	Value
Publication number	US-10816547-B2
Application number	US-201615099371-A
Country	US
Kind code	B2
Filing date	Apr 14, 2016
Priority date	Oct 14, 2013
Publication date	Oct 27, 2020
Grant date	Oct 27, 2020

Abstract

The present invention relates to compositions which may comprise a non-naturally occurring or engineered artificial transcription factor, wherein the transcription factor may comprise a sequence specific DNA binding domain, a sliding domain, and one or more linkers, wherein the DNA binding domain and the sliding domain are operably connected by the one or more linkers, and uses thereof. Methods involving the use of a non-naturally occurring or engineered artificial transcription factors and pharmaceutical compositions, methods for treating cancer, a degenerative disease, a genetic disease or an infectious disease as well as diagnostic methods are also contemplated by the present invention.

First claim

What is claimed is:

1. A composition comprising a non-naturally occurring or engineered artificial transcription factor, wherein the transcription factor comprises a sequence specific DNA binding domain comprising KRARNTEAARRSRAR (SEQ ID NO: 20), a sliding domain comprising KRRR (SEQ ID NO: 2), and one or more linkers, wherein the DNA binding domain and the sliding domain are operably connected by the one or more linkers.

2. The composition of claim 1 , wherein the composition comprises a sequence selected from the group consisting of KRARNTEAARRSRAR-GSGSGS-KRRR (SEQ ID NO: 17) and KRARNTEAARRSRAR-GSGSGS-GVQSLKRRRCF (SEQ ID NO: 53).

3. The composition of claim 1 , wherein the one or more linkers has a length of one to eighteen Angstroms.

4. The composition of claim 1 , wherein the one or more linkers has a length of one to twelve amino acids.

5. The composition of claim 1 , wherein the one or more linkers is selected from the group consisting of poly alanine (4-6 residues) (SEQ ID NO: 28) and poly glycine (4-6 residues) (SEQ ID NO: 29).

6. The composition of claim 1 , further comprising a cargo linked to an amino acid residue of the artificial transcription factor.

7. The composition of claim 6 , wherein the cargo is attached to the artificial transcription factor at a site selected from the group consisting of the DNA binding domain and the one or more linkers.

8. The composition of claim 6 , wherein the cargo is attached to the DNA binding domain.

9. The composition of claim 6 , wherein the cargo is a therapeutic agent.

10. The composition of claim 6 , wherein the cargo is selected from the group consisting of a small molecule, a nucleic acid, a peptide, and an analog or derivative thereof.

11. The composition of claim 10 , wherein the small molecule is a drug.

12. The composition of claim 6 , wherein the cargo is naturally occurring.

13. The composition of claim 6 , wherein the artificial transcription factor or the cargo comprises a nuclear localization signal (NLS).

14. The composition of claim 6 , wherein the composition is capable of penetrating a cell membrane.

15. The composition of claim 10 , wherein the peptide is an antibody.

16. The composition of claim 15 , wherein the antibody targets a nucleic acid binding protein.

17. The composition of claim 10 , wherein the peptide is a nucleic acid binding protein.

18. The composition of claim 17 , wherein the nucleic acid binding protein is selected from the group consisting of a DNA gyrase, a transcription activator-like effector (TALE) DNA binding protein, a transcription factor, a zinc finger binding protein and a CRISPR-Cas complex.

19. The composition of claim 10 , wherein the peptide is selected from the group consisting of Gemifloxacin, Norfloxacin, an adenovirus proteinase (AVP), protein VI, pVI, and streptavidin.

20. The composition of claim 10 , wherein the nucleic acid is selected from the group consisting of a double stranded DNA, a single stranded DNA and a RNA.

21. The composition of claim 20 , wherein the nucleic acid contains a residue with a modification selected from the group consisting of a 2′ 0-Me, a locked nucleic acid (LNA), and a minor-grove-binding moiety modification.

22. The composition of claim 6 , wherein the cargo is a particle.

23. The composition of claim 22 , wherein the particle is selected from the group consisting of a nanoparticle, a bead, an organelle and a large protein complex.

24. The composition of claim 6 , wherein the cargo is light-activated.

25. The composition of claim 24 , wherein the light-activated cargo is a major light-harvesting complex (LHCII).

26. The composition of claim 6 , wherein light cleaves the one or more linkers to release the cargo.

27. The composition of claim 1 , further comprising a fluorescent label.

28. The composition of claim 27 , wherein the fluorescent label is selected from the group consisting of a perylene and a terrylen.

29. The composition of claim 27 , wherein the fluorescent label induces free radical formation.

30. A capsule comprising the composition of claim 1 encapsulated by a molecular capsule.

31. The capsule of claim 30 , wherein the molecular capsule is selected from the group consisting of a calixarene, a cucurbituril, a cyclodextrin and a pillararene.

32. The capsule of claim 31 , wherein the cucurbituril comprises 5, 6, 7, 8 or 10 repeat units.

Assignees

• Broad Inst Inc
• Massachusetts Inst Technology

Inventors

• Blainey Paul
• Kulesa Anthony
• Xiong Kan

Classifications

• C07K14/4705 Primary

  stimulating, promoting or activating activity · CPC title

• C07K14/39

  from yeasts · CPC title

• C12Q1/686

  Polymerase chain reaction [PCR] · CPC title

• C12Q1/6848

  characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction · CPC title

• C12N15/67

  General methods for enhancing the expression · CPC title